This year, according to TNBCF Medical Advisory Board Member, Eric Winer, MD, there was no study presented on TNBC that represents a major step forward or will have a significant immediate impact on clinical practice. That statement is true for the meeting as a whole in which the majority of studies were focused on incremental advances, especially in the area of targeted therapies.
Friday, June 17, 2011
TNBC News from ASCO 2011
The Triple Negative Foundation has an excellent overview of research presented at the annual meeting of the American Society for Clinical Oncology (ASCO) June 2 through 7, 2011. While several studies dealt with TNBC, none was groundbreaking. According to the Foundation: